TuHURA Biosciences files FDA IND for TBS-2025 VISTA antibody in AML, blood cancers

TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc.

HURA

0.00
  • Tuhura Biosciences filed an IND with the FDA for TBS-2025, a VISTA-inhibiting antibody, in molecularly defined AML subsets.
  • The FDA declined a requested meeting, opting to provide written feedback on the proposed Phase 1b/2 AML plan next month.
  • Tuhura targets starting the Phase 1b/2 trial in 2H 2026, including monotherapy in relapsed/refractory AML with potential expansion for accelerated approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606150745PR_NEWS_USPR_____LA83185) on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.